文献速递白血病

基于转录组的慢性髓性白血病无治疗缓解多变量预测模型的开发与外部验证

Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia.
PubMed 文献 · J Clin Oncol · 2026-06-09

该研究在STIM2试验96例伊马替尼停药患者中开发基于外周血细胞转录组的50基因特征预测2年无治疗缓解(TFR),并在70例独立真实世界队列中外部验证。高TFR特征组富集髓系免疫细胞和NKT细胞及Hedgehog信号,低TFR特征组富集淋系细胞及mTOR信号。

要点

  • 停药时外周血转录组50基因特征可预测CML患者2年TFR,外部验证AUROC 0.71。
  • 高TFR特征组富集髓系免疫细胞、NKT细胞和Hedgehog信号,多克隆性更高。
  • 低TFR特征组富集淋系细胞、mTOR信号和氧化磷酸化激活趋势。

核心结论

  • 停药时转录组分析可预测CML患者TFR结局,并为持续TFR机制提供生物学线索。

研究设计与样本

  • 多中心STIM2试验96例伊马替尼停药患者用于开发转录组模型,独立真实世界队列70例用于外部验证。

主要发现

  • 50基因特征区分2年持续TFR与分子复发,训练集AUROC 0.83(95%CI 0.73-0.93),内部验证集0.75(95%CI 0.55-1.00)。
  • 外部验证队列2年TFR二分类预测AUROC总体0.71(95%CI 0.58-0.83),伊马替尼治疗患者0.77(95%CI 0.61-0.92)。
  • 高TFR特征组髓系免疫细胞和NKT细胞比例更高,Hedgehog信号富集;低TFR特征组淋系细胞比例更高,mTOR信号富集及氧化磷酸化激活趋势。
  • 高TFR特征组T细胞受体和免疫球蛋白重链 repertoire 多克隆性显著更高。

关键数值与推荐

  • 50基因特征用于预测2年TFR,训练集AUROC 0.83(95%CI 0.73-0.93),内部验证集0.75(95%CI 0.55-1.00)。

临床怎么用

  • 停药时外周血转录组检测可能辅助识别适合尝试TFR的CML患者。
  • 高TFR特征提示髓系免疫/NKT细胞及Hedgehog信号参与持续缓解,低TFR特征提示淋系/mTOR信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment-free remission (TFR) is a major therapeutic objective in chronic myeloid leukemia (CML). However, nearly 50% of patients relapse after tyrosine kinase inhibitor (TKI) discontinuation, and no robust predictive biomarker is currently available. METHODS: We profiled peripheral blood cell transcriptomes at imatinib (IMA) discontinuation in patients from the multicenter STIM2 trial (n = 96) to develop a transcriptome-based model predicting TFR by 2 years. A DESEQ2-based machine learning approach was compared with classical machine learning algorithms. The signature was then externally validated in an independent real-world cohort of patients attempting IMA or nilotinib cessation (n = 70). The biologic processes associated with the signature were further explored. RESULTS: We identified a 50-gene signature discriminating patients with sustained 2-year TFR from those experiencing molecular relapse (area under the receiver operating characteristic curve [AUROC], 0.83 [95% CI, 0.73 to 0.93] and 0.75 [95% CI, 0.55 to 1.00] in the training and internal validation cohorts, respectively). The discriminative performance was confirmed in the external test cohort, both as a binary predictor of 2-year TFR (AUROC, 0.71 [95% CI, 0.58 to 0.83] overall; 0.77 [95% CI, 0.61 to 0.92] in IMA-treated patients) and as a time-to-event predictor (log-rank P = .0042). The high TFR-signature group showed a higher proportion of myeloid immune cells and natural killer T cells, with an enrichment in Hedgehog signaling, whereas the low TFR-signature group demonstrated a higher proportion of lymphoid cells with an enrichment in mTOR signaling and a trend for oxidative phosphorylation activation. T-cell receptor and immunoglobulin heavy-chain repertoire analyses showed significantly greater polyclonality in the high TFR-signature group. CONCLUSION: These findings demonstrate that transcriptomic profiling at TKI discontinuation can predict TFR outcomes in patients with CML and provide biologic insights into the mechanisms underlying sustained TFR.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Alcazer V, Dulucq S, Mosnier I, et al. Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia. J Clin Oncol. 2026. PMID: 42454992. doi:10.1200/JCO-25-02948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。